Deep Dive Into Clorox Stock: Analyst Perspectives (6 Ratings)
Portfolio Pulse from Benzinga Insights
In the last three months, Clorox (NYSE:CLX) received 6 analyst ratings, showing a shift towards a neutral stance with 4 indifferent ratings recently. The average 12-month price target for Clorox is now $147.83, up 9.5% from the previous $135.00, with a high estimate of $170.00 and a low of $118.00. Analysts from firms like Jefferies, Goldman Sachs, DA Davidson, UBS, JP Morgan, and Barclays have updated their ratings and price targets, reflecting changes in market conditions and Clorox's performance. Clorox's financial performance shows a notable revenue growth of 16.04% as of December 31, 2023, but challenges in net margin, debt management, and ROA, despite an exceptional ROE of 1162.5%.
March 26, 2024 | 2:00 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Clorox has received mixed analyst ratings, with a notable increase in its average price target to $147.83, reflecting a positive outlook from some analysts despite challenges in profitability and debt management.
The mixed analyst ratings with a shift towards neutral positions and the increase in the average price target suggest a cautiously optimistic outlook for Clorox. However, the financial challenges highlighted, such as below-average net margin and high debt-to-equity ratio, may temper short-term stock performance. The significant revenue growth and exceptional ROE indicate strong aspects of the company's financial health, but the overall impact on the stock price in the short term is likely to be neutral due to the balancing of positive and negative factors.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100